<SEC-DOCUMENT>0001193125-24-110465.txt : 20240425
<SEC-HEADER>0001193125-24-110465.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240424174026
ACCESSION NUMBER:		0001193125-24-110465
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240424
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		24872108

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d107441d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as April 24, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d107441dex991.htm">Immutep Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in
First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April 24, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d107441dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107441dsp04aa.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Positive Preliminary Topline Results from </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase IIb Trial Evaluating Efti in Combination With </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in First Line Metastatic Head and Neck </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Squamous Cell Carcinoma Patients with Negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data from efti in combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in first
line head and neck squamous cell carcinoma patients who do not express <FONT STYLE="white-space:nowrap">PD-L1</FONT> <FONT STYLE="white-space:nowrap">(TACTI-003,</FONT> Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the
study </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data collection, cleaning, and analysis continues and additional data from
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> (Cohorts A&nbsp;&amp; B), including complete response rate, will be released in H1 CY2024 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; April</B><B></B><B>&nbsp;24, 2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous
cell carcinoma patients (1L HNSCC) with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investigational immuno-oncology
combination utilizing Immutep&#146;s MHC Class&nbsp;II agonist and MSD&#146;s <FONT STYLE="white-space:nowrap">PD-1</FONT> therapy demonstrates an overall response rate (ORR) of 26.9% and disease control rate (DCR) of 57.7% in 26 patients whose
tumours do not express <FONT STYLE="white-space:nowrap">PD-L1</FONT> (Combined Positive Score [CPS] &lt;1), according to RECIST 1.1, which compares favourably to historical controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Martin&nbsp;Forster&nbsp;of the UCL Cancer Institute and University College London Hospital NHS Foundation, London, UK, and <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> Investigator, stated, &#147;These preliminary topline results in the first line setting for patients with head and neck squamous cell cancers that do not express
<FONT STYLE="white-space:nowrap">PD-L1</FONT> are encouraging. Head and neck squamous cell carcinomas are a heterogenous disease that represent a high unmet medical need regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. This is
especially the case for patients with tumours that do not express <FONT STYLE="white-space:nowrap">PD-L1</FONT> and those that cannot receive chemotherapy. The ability of efti to work with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> to potentially improve patients&#146; clinical responses and expand patient populations that respond to the latter, without
using chemotherapy, is promising.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This new data adds to the body of evidence that efti&#146;s novel activation of antigen-presenting cells provides
a powerful boost to the immune system, which enhances the potential of immune checkpoint inhibitors. Fundamentally, efti is leading to a significant expansion of memory cytotoxic T cells that <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapies can act upon. Importantly, as the only MHC Class&nbsp;II agonist in clinical development today, efti is generating a broad anti-cancer immune response in a unique and safe manner across
all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, even in tumours with negative expression (CPS&lt;1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of 33 patients with
recurrent or metastatic HNSCC have been enrolled into Cohort B. The 26 patients reported on today represent those currently available with sufficiently long enough follow up time as per protocol and where the data cleaning has sufficiently
progressed at the time of data <FONT STYLE="white-space:nowrap">cut-off</FONT> in February. The final number of evaluable patients in Cohort B is expected to be higher and additional data, including complete response rate, will be released together
with Cohort A data. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107441dsp04aa.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the randomized Cohort A of the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial evaluating the
safety and efficacy of efti in combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> as compared to KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> monotherapy, 138 patients with <FONT
STYLE="white-space:nowrap">PD-L1</FONT> positive tumours have been enrolled at over 30 centres globally. Patients in Cohort A are stratified by CPS <U>&gt;</U>1, CPS <FONT STYLE="white-space:nowrap">1-19,</FONT> and CPS <U>&gt;</U>20, and the
clinical results for these three CPS groups will be evaluated. The <FONT STYLE="white-space:nowrap">cut-off</FONT> for primary analysis according to the trial protocol is defined as after all subjects have completed at least three cycles of
treatment (18 weeks in total) or discontinued the trial. Thereafter data collection and data cleaning need to be completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data collection, cleaning,
and analysis continue for <FONT STYLE="white-space:nowrap">TACTI-003,</FONT> and the Company expects to report the primary endpoint (overall response rate according to RECIST1.1) from Cohorts A&nbsp;&amp; B in H1 CY2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer by incidence worldwide, with 890,000 new cases and 450,000 deaths reported in
2018.<SUP STYLE="font-size:75%; vertical-align:top">1,2,3</SUP> It is an aggressive, genetically complex, and difficult to treat cancer.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> Furthermore, HNSCC is associated with high levels of
psychological distress and compromised quality of life (QOL).<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> As such, HNSCC patients need improved treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti has received FDA Fast Track designation in 1L HNSCC regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> trial is
an ongoing Phase IIb study evaluating eftilagimod alpha (efti), Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The
randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (Combined Positive Score [CPS] &#8805;1)
tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is Overall Response Rate of evaluable patients according to RECIST 1.1. Secondary endpoints include Overall Survival,
Overall Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. The primary analysis according to the trial protocol will be performed after all subjects have completed at least three cycles of treatment (18 weeks in
total) or discontinued the trial, and all relevant data for the primary endpoint has been collected, cleaned, and analysed. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107441dsp04aa.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>c.strong@morrowsodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
<I>Int. J. Cancer</I> 144, 1941&#150;1953 (2019). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA <I>Cancer J. Clin. 68</I>, 394&#150;424 (2018). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ferlay, J. et al. Global Cancer Observatory: Cancer Today. Lyon, France: <I>International Agency for Research
on Cancer</I> (<I>IARC)</I> https://gco.iarc.fr/today (2018). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alsahafi, E., Begg, K., Amelio, I. et al. Clinical update on head and neck cancer: molecular biology and
ongoing challenges. <I>Cell Death Dis</I> 10, 540 (2019). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Johnson, D.E., Burtness, B., Leemans, C.R. et al. Head and neck squamous cell carcinoma. <I>Nat Rev Dis
Primers</I> 6, 92 (2020). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g107441dsp04aa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107441dsp04aa.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( &P#10,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M ,/7/$4.D$0JHEN2,A.RCU-1*:B85:RIG-+XLUIU>94B,:$;L1\#/3OFLE4D
M<JQ%1['5:7K$ETZ6][;-:W3+N56Z..Y'^%:QE<[*=1O26C->K-0H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0\4 >9W.H!]0U%;F
M!9?/D*;V.&C )'!KF;]YIGE3G[\DSK&\,Z;%IS)'$2P <.6))(Z9]O:M>1)7
M.WV,5"Z./76+Z[U6TN)IBTD;J%P ,#/(P*RO>1Q^TDY)L]/'2ND],=0,* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_P"NKC!WNS:E2<FI2.ZQBMSN%H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M$Y!_D* /0: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6-PQ "MSQ]: +GPX_P"1;E!_Y^6_]!6@#AM,N4T7QDDUR"$M[AU?CH.5S^M
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#D/\
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M];78/^$ZB_Y\7_[^#_"CVJ#ZVNP?\)U%_P ^+_\ ?P?X4>U0?6UV#_A.HO\
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ML'_"=1?\^+_]_!_A1[5!];78/^$ZB_Y\7_[^#_"CVJ#ZVNP?\)U%_P ^+_\
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M$ _X0W2_[T__ 'V/\*/9Q#V$ _X0W2_[T_\ WV/\*/9Q#V$ _P"$-TO^]/\
M]]C_  H]G$/80#_A#=+_ +T__?8_PH]G$/80#_A#=+_O3_\ ?8_PH]G$/80#
M_A#=+_O3_P#?8_PH]G$/80#_ (0W2_[T_P#WV/\ "CV<0]A /^$-TO\ O3_]
M]C_"CV<0]A /^$-TO^]/_P!]C_"CV<0]A /^$-TO^]/_ -]C_"CV<0]A /\
MA#=+_O3_ /?8_P */9Q#V$ _X0W2_P"]/_WV/\*/9Q#V$ _X0W2_[T__ 'V/
M\*/9Q#V$ _X0W2_[T_\ WV/\*/9Q#V$ _P"$-TO^]/\ ]]C_  H]G$/80#_A
M#=+_ +T__?8_PH]G$/80#_A#=+_O3_\ ?8_PH]G$/80#_A#=+_O3_P#?8_PH
M]G$/80#_ (0W2_[T_P#WV/\ "CV<0]A /^$-TO\ O3_]]C_"CV<0]A /^$-T
MO^]/_P!]C_"CV<0]A /^$-TO^]/_ -]C_"CV<0]A /\ A#=+_O3_ /?8_P *
M/9Q#V$ _X0W2_P"]/_WV/\*/9Q#V$ _X0W2_[T__ 'V/\*/9Q#V$ _X0W2_[
MT_\ WV/\*/9Q#V$ _P"$-TO^]/\ ]]C_  H]G$/80#_A#=+_ +T__?8_PH]G
M$/80#_A#=+_O3_\ ?8_PH]G$/80#_A#=+_O3_P#?8_PH]G$/80#_ (0W2_[T
M_P#WV/\ "CV<0]A /^$-TO\ O3_]]C_"CV<0]A /^$-TO^]/_P!]C_"CV<0]
MA /^$-TO^]/_ -]C_"CV<0]A /\ A#=+_O3_ /?8_P */9Q#V$ _X0W2_P"]
M/_WV/\*/9Q#V$ _X0W2_[T__ 'V/\*/9Q#V$ _X0W2_[T_\ WV/\*/9Q#V$
M_P"$-TO^]/\ ]]C_  H]G$/80#_A#=+_ +T__?8_PH]G$/80#_A#=+_O3_\
M?8_PH]G$/80#_A#=+_O3_P#?8_PH]G$/80#_ (0W2_[T_P#WV/\ "CV<0]A
M/^$-TO\ O3_]]C_"CV<0]A /^$-TO^]/_P!]C_"CV<0]A /^$-TO^]/_ -]C
M_"CV<0]A /\ A#=+_O3_ /?8_P */9Q#V$ _X0W2_P"]/_WV/\*/9Q#V$ _X
M0W2_[T__ 'V/\*/9Q#V$ _X0W2_[T_\ WV/\*/9Q#V$ _P"$-TO^]/\ ]]C_
M  H]G$/80#_A#=+_ +T__?8_PH]G$/80#_A#=+_O3_\ ?8_PH]G$/80#_A#=
M+_O3_P#?8_PH]G$/80#_ (0W2_[T_P#WV/\ "CV<0]A /^$-TO\ O3_]]C_"
MCV<0]A /^$-TO^]/_P!]C_"CV<0]A /^$-TO^]/_ -]C_"CV<0]A /\ A#=+
M_O3_ /?8_P */9Q#V$ _X0W2_P"]/_WV/\*/9Q#V$ _X0W2_[T__ 'V/\*/9
MQ#V$ _X0W2_[T_\ WV/\*/9Q#V$!/^$-TO\ O3_]]C_"CV<1>P@(W@W2\_>G
-_P"^Q_A2Y$)T(7/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
